Taken together, these findings clearly indicate the potential importance of a dysregulated GSK3β/EZH2 axis in the progression of NPC, which might hold significant promise for identifying critical molecular targets and improving NPC therapy. Here, EZH2 is linked to nasopharyngeal carcinoma.